UCLA Finds Way to Beat Prostate Cancer Drug Resistance

Scientists just figured out how to make one of medicine's most promising cancer treatments work better against a disease that kills over 34,000 American men each year.

Researchers at UCLA Health discovered that pairing antibody-drug conjugates with a second medication can overcome the resistance that has limited these precision therapies in treating advanced prostate cancer. In both laboratory and animal studies, the combination triggered dramatically more cancer cell death than either drug alone.

Antibody-drug conjugates work like smart missiles. They deliver powerful chemotherapy directly to cancer cells while leaving healthy tissue mostly untouched. These therapies have transformed treatment for breast, bladder and blood cancers, but they've barely made a dent in metastatic castration-resistant prostate cancer, the most aggressive form of the disease.

Dr. John Lee and his team at the UCLA Health Jonsson Comprehensive Cancer Center wanted to understand why. They analyzed tumor samples from patients with advanced prostate cancer and found three proteins that these smart drugs target sitting right next to each other on cancer cells. That meant multiple therapies could hit the same tumor simultaneously.

Then they tested dozens of drug combinations to find pairs that worked better together. One stood out: pairing DNA-damaging drugs with a compound that blocks BCL-XL, a protein cancer cells use as a shield against death.

Cancer cells are surprisingly resilient. Even when their DNA gets damaged, they activate backup survival systems to stay alive. Blocking BCL-XL removes one of those escape routes, making it much harder for damaged tumor cells to recover.

The results were striking. In mice with advanced prostate tumors, the combination slowed tumor growth significantly more than either therapy by itself. The researchers also discovered that tumors with an intact TP53 gene responded especially well, suggesting genetic testing could eventually identify which patients would benefit most.

The Bright Side

This research represents a shift in how scientists approach cancer drug development. Instead of starting from scratch with entirely new therapies, the UCLA team found a way to make existing treatments work better by understanding the biology of why they fail.

The flexibility of antibody-drug conjugates means researchers can mix and match different drug payloads and target combinations. That opens dozens of potential pathways for creating more effective treatments tailored specifically to how prostate cancer behaves.

The team is now engineering next-generation antibody-drug conjugates that incorporate these findings and testing additional combinations that could improve results even further.

For men battling metastatic castration-resistant prostate cancer, this research offers something that's been in short supply: a clear path forward when standard treatments stop working.